SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76913.50
582.86 (-0.75%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	7,894 Small Cap	819.30 (1.92%)	82.79	4.85	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Shilpa Medicare Ltd.	Q V PT	7,958 Small Cap	406.90 (0.67%)	52.69	3.17	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Jupiter Life Line Hospitals Ltd.	Q V PT	8,052 Small Cap	1,228.05 (-0.80%)	43.49	5.21	18.02	36.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Marksans Pharma Ltd.	Q V PT	8,368 Small Cap	184.65 (-1.55%)	34.5	5.46	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Healthcare Global Enterprises Ltd.	Q V+ PT	8,548 Small Cap	572.55 (0.58%)	366.34	5.29	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	8,616 Small Cap	547.40 (0.78%)	68.92	3.56	12.22	23.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Procter & Gamble Health Ltd.	Q V PT	8,623 Small Cap	5,194.55 (1.33%)	28.99	12.2	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Viyash Scientific Ltd.	Q V PT	8,919 Small Cap	204.15 (-1.52%)	117.91	10.07	5.64	-18.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Strides Pharma Science Ltd.	Q V+ PT	9,552 Small Cap	1,036.35 (-1.60%)	52.93	2.94	4.81	-16.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Metropolis Healthcare Ltd.	Q V+ PT	9,884 Small Cap	476.75 (-0.49%)	59.04	6.6	9.22	2.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Park Medi World Ltd.	Q V PT	9,945 Small Cap	230.25 (-2.10%)	1415.1	11.3	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	CORONA Remedies Ltd.	Q V+ PT	10,550 Small Cap	1,725 (2.12%)	69.31	14.75	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Vijaya Diagnostic Centre Ltd.	Q V PT	10,897 Small Cap	1,126.95 (1.27%)	67.49	11.86	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,973 Small Cap	4,764.65 (-0.72%)	42.86	24.46	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Concord Biotech Ltd.	Q V PT	11,928 Small Cap	1,140.15 (0.73%)	37.89	6.26	18.56	18.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Indegene Ltd.	Q V+ PT	12,034 Small Cap	499.55 (0.84%)	27.19	4.02	34.59	31.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Rainbow Childrens Medicare Ltd.	Q V PT	12,731 Small Cap	1,253.60 (-0.51%)	52.18	7.76	15.91	24.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Alivus Life Sciences Ltd.	Q V PT	12,734 Small Cap	1,037.50 (3.19%)	22.7	3.9	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Caplin Point Laboratories Ltd.	Q V PT	13,003 Small Cap	1,710.60 (-0.88%)	21.37	3.94	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	Dr. Agarwals Health Care Ltd.	Q V PT	14,084 Small Cap	444.35 (0.62%)	111.04	7.09	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	Jubilant Pharmova Ltd.	Q V+ PT	14,761 Small Cap	926.75 (0.01%)	N/A	6.56	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Alembic Pharmaceuticals Ltd.	Q V+ PT	14,831 Small Cap	754.50 (-0.91%)	23.8	2.74	7.69	-8.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Poly Medicure Ltd.	Q V PT	15,316 Small Cap	1,511.05 (-0.59%)	45.05	5.19	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Rubicon Research Ltd.	Q V+ PT	16,019 Small Cap	970.30 (-0.20%)	95.81	12.41	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Granules India Ltd.	Q V+ PT	17,327 Small Cap	699.25 (-0.90%)	43.64	4.42	5.58	-0.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Eris Lifesciences Ltd.	Q V PT	18,326 Small Cap	1,322.75 (0.56%)	42.21	5.03	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Cohance Lifesciences Ltd.	Q V+ PT	18,476 Small Cap	482.95 (3.22%)	88.75	4.69	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	Syngene International Ltd.	Q V+ PT	18,888 Small Cap	467.90 (8.30%)	57.1	3.75	10.89	4.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Neuland Laboratories Ltd.	Q V+ PT	19,243 Small Cap	14,998.70 (2.36%)	105.42	11.38	14.13	64.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Natco Pharma Ltd.	Q V PT	19,628 Small Cap	1,095.85 (0.20%)	12.58	2.23	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
RPG Life Sciences	2,297.45	13.59%
Syngene Internation.	467.90	8.30%
Guj. Kidney & Super	125.40	5.38%
Kopran	164.70	5.14%
Aarti Pharmalabs	744.25	4.91%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
3B Blackbio Dx	1,206.60	-4.77%
Lincoln Pharma	645.40	-4.19%
Sun Pharma Adv. Res	142.85	-3.71%
Laxmi Denta	199	-3.40%
Guj. Themis Biosyn	363.75	-3.22%

News about Top Pharma Companies in India

Apr, 2026

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

Apr, 2026

Indegene reports 32% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

Apr, 2026

Granules India gains on reporting 33% rise in Q4 consolidated net profit

Consolidated total income of the company increased by 23.35% at Rs 1,479.38 crore for Q4FY26

Apr, 2026

Syngene Internation. - Quaterly Results

The company's total revenue for the quarter ended March 2026 saw a slight change in the total revenue, having registered a total revenue of Rs. 9600.00 millions.The Net Profit of the company registered a slight decline of -15.02% to Rs. 1482.00 millions from Rs. 1744.00 millions.Operating profit for the quarter ended March 2026 decreased to 3059.00 millions as compared to 3284.00 millions of corresponding quarter ended March 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	9600.00	9484.00	1.22	34238.00	33733.00	1.50	34238.00	33733.00	1.50
Other Income	216.00	184.00	17.39	669.00	705.00	-5.11	669.00	705.00	-5.11
PBIDT	3059.00	3284.00	-6.85	8815.00	9881.00	-10.79	8815.00	9881.00	-10.79
Interest	65.00	101.00	-35.64	260.00	312.00	-16.67	260.00	312.00	-16.67
PBDT	2920.00	3183.00	-8.26	7823.00	9889.00	-20.89	7823.00	9889.00	-20.89
Depreciation	953.00	896.00	6.36	3871.00	3673.00	5.39	3871.00	3673.00	5.39
PBT	1967.00	2287.00	-13.99	3952.00	6216.00	-36.42	3952.00	6216.00	-36.42
TAX	485.00	543.00	-10.68	903.00	1536.00	-41.21	903.00	1536.00	-41.21
Deferred Tax	148.00	130.00	13.85	222.00	339.00	-34.51	222.00	339.00	-34.51
PAT	1482.00	1744.00	-15.02	3049.00	4680.00	-34.85	3049.00	4680.00	-34.85
Equity	4029.00	4025.00	0.10	4029.00	4025.00	0.10	4029.00	4025.00	0.10
PBIDTM(%)	31.86	34.63	-7.98	25.75	29.29	-12.10	25.75	29.29	-12.10

Apr, 2026

Granules India informs about press release

With refer to the audited financial results for the fourth quarter and financial year ended on March 31, 2026, submitted today i.e., on April 29, 2026, Granules India has enclosed the press release to the Analysts/ Investors. This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Granules India reports 33% rise in Q4 consolidated net profit

Consolidated total income of the company increased by 23.35% at Rs 1,479.38 crore for Q4FY26

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	241 Crore
2	Shree Ganesh Remedies Ltd.	661 Crore
3	Fabtech Technologies Ltd.	750 Crore
4	Sigachi Industries Ltd.	767 Crore
5	Kopran Ltd.	795 Crore
6	Anuh Pharma Ltd.	822 Crore
7	Health X Platform Ltd.	884 Crore
8	Themis Medicare Ltd.	901 Crore
9	Wanbury Ltd.	901 Crore
10	Fermenta Biotech Ltd.	916 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,431	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,192	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,304	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,247	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,099	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,310	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,808	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	19.45

You’ve reached your free data limit. Unlock unlimited data views for free. Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

Indegene reports 32% fall in Q4 consolidated net profit

Granules India gains on reporting 33% rise in Q4 consolidated net profit

Syngene Internation. - Quaterly Results

Granules India informs about press release

Granules India reports 33% rise in Q4 consolidated net profit

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.